Trimetazidine
Trimetazidine (pronunciation: /triːmɛtəˈziːdiːn/) is a pharmacological agent used primarily in the treatment of angina pectoris. It is classified as an anti-ischemic (an agent that improves myocardial glucose utilization through inhibition of fatty acid metabolism) under the ATC code C01EB15.
Etymology
The term "Trimetazidine" is derived from its chemical structure, which consists of three methoxy groups (tri-meth) and an azidine group.
Pharmacology
Trimetazidine works by improving the metabolism of cells in the heart and brain. It is a selective inhibitor of the enzyme long-chain 3-ketoacyl CoA thiolase, which is involved in fatty acid oxidation. By inhibiting this enzyme, Trimetazidine shifts the energy substrate preference from fatty acids to glucose, which requires less oxygen to be metabolized. This shift in metabolism reduces the severity and frequency of angina attacks.
Clinical Use
Trimetazidine is used as a long-term treatment of angina pectoris, and can be used in combination with other anti-anginal drugs. It is also used in vertigo, tinnitus, and Meniere's disease.
Side Effects
Common side effects of Trimetazidine include nausea, vomiting, abdominal pain, and headache. In rare cases, it can cause Parkinsonism.
Related Terms
- Angina Pectoris
- Pharmacology
- Long-chain 3-ketoacyl CoA thiolase
- Vertigo
- Tinnitus
- Meniere's disease
- Parkinsonism
External links
- Medical encyclopedia article on Trimetazidine
- Wikipedia's article - Trimetazidine
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski